Published in J Clin Epidemiol on December 23, 2008
Estimated mortality of adult HIV-infected patients starting treatment with combination antiretroviral therapy. Sex Transm Infect (2012) 1.41
Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. PLoS Med (2014) 1.40
Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics. Int J Epidemiol (2012) 1.11
Impact of definitions of loss to follow-up on estimates of retention, disease progression, and mortality: application to an HIV program in Mozambique. Am J Epidemiol (2013) 1.11
Drug use and receipt of highly active antiretroviral therapy among HIV-infected persons in two U.S. clinic cohorts. PLoS One (2011) 1.10
Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean. J Int AIDS Soc (2015) 0.88
A Comparison of Seven Cox Regression-Based Models to Account for Heterogeneity Across Multiple HIV Treatment Cohorts in Latin America and the Caribbean. AIDS Res Hum Retroviruses (2015) 0.83
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 46.18
1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep (1992) 22.29
Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med (2007) 19.78
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56
Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med (1997) 16.44
Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med (2006) 8.25
Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med (2003) 8.05
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA (2001) 7.63
The cost of dichotomising continuous variables. BMJ (2006) 5.12
Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 3.69
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme. Int J Epidemiol (2007) 3.22
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA (2001) 2.95
Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. J Infect Dis (2006) 2.54
Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy. Stat Med (2004) 2.26
Prognostic model for HIV-1 disease progression in patients starting antiretroviral therapy was validated using independent data. J Clin Epidemiol (2005) 1.72
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 x 10(6) /l. AIDS (2002) 1.38
Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: disease progression, treatment durability, and drug toxicity. Clin Infect Dis (2003) 1.32
Zidovudine and stavudine sequencing in HIV treatment planning: findings from the CHORUS HIV cohort. J Acquir Immune Defic Syndr (2001) 1.29
Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis (2006) 1.21
The cost of checking proportional hazards. Stat Med (2008) 0.98
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Tuberculosis. Lancet (2003) 6.39
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med (2006) 5.02
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (2004) 4.64
Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis (2007) 4.10
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr (2005) 3.92
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS (2002) 3.45
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis (2007) 3.36
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? J Gen Intern Med (2006) 3.25
Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care (2005) 3.19
Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis (2008) 3.17
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol (2008) 3.14
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis (2005) 2.92
Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs (2006) 2.89
Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol (2006) 2.81
Survival of patients with pulmonary tuberculosis: clinical and molecular epidemiologic factors. Clin Infect Dis (2002) 2.80
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr (2006) 2.78
Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr (2007) 2.73
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis (2004) 2.71
Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clin Infect Dis (2002) 2.68
Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr (2007) 2.53
Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS (2003) 2.52
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol (2006) 2.46
Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis (2004) 2.44
Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med (2004) 2.40
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS (2008) 2.25
Antiretroviral medication errors remain high but are quickly corrected among hospitalized HIV-infected adults. Clin Infect Dis (2012) 2.24
Lack of weight gain and relapse risk in a large tuberculosis treatment trial. Am J Respir Crit Care Med (2006) 2.23
Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS (2009) 2.22
Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr (2012) 2.19
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med (2009) 2.18
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother (2012) 2.16
Contemporary costs of HIV healthcare in the HAART era. AIDS (2010) 2.16
Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS (2008) 2.14
Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS (2004) 2.11
Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis (2006) 2.08
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis (2009) 2.04
Comparing different measures of retention in outpatient HIV care. AIDS (2012) 1.98
Latent TB infection treatment acceptance and completion in the United States and Canada. Chest (2009) 1.97
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis (2009) 1.95
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy. Clin Infect Dis (2011) 1.91
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic. AIDS (2006) 1.82
Immune reconstitution inflammatory syndrome: risk factors and treatment implications. J Acquir Immune Defic Syndr (2007) 1.82
CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis (2005) 1.81
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Arch Intern Med (2007) 1.78
Retention among North American HIV-infected persons in clinical care, 2000-2008. J Acquir Immune Defic Syndr (2013) 1.73
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care. J Infect Dis (2009) 1.72
Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin Infect Dis (2008) 1.72
The economic burden of late entry into medical care for patients with HIV infection. Med Care (2010) 1.69
Structures of care in the clinics of the HIV Research Network. AIDS Patient Care STDS (2008) 1.69
Extensively drug-resistant tuberculosis: are we learning from history or repeating it? Clin Infect Dis (2007) 1.69
Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr (2006) 1.66
An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS (2013) 1.64
Hospitalizations for metabolic conditions, opportunistic infections, and injection drug use among HIV patients: trends between 1996 and 2000 in 12 states. J Acquir Immune Defic Syndr (2005) 1.64
Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients. J Infect Dis (2003) 1.63
Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest (2013) 1.62
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Interval and clinical cohort studies: epidemiological issues. AIDS Res Hum Retroviruses (2007) 1.61
Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med (2006) 1.55
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis (2003) 1.53
Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS (2008) 1.52